BioBytes: What are biosimilars?

Biosimilars, also known as follow-on biologics, may eventually expand access and provide patients a more affordable alternative to innovative, lifesaving medicines. However, there are a few important safeguards that must be put into place before these similar but not the same versions of biologics can be safely introduced to the public. Join Dr. Targan as he explains the complex nature of biologics and the steps that need to be taken by Congress and the FDA to ensure that biosimilars are safe and effective while ensuring the continued development of cutting-edge medicines.

Category:

Science & Technology

Tags:

• BIO
• biogenerics
• biologics
• Biosimilars
• biotech
• biotech innovation
• biotechnology
• cancer
• DNA
• FDA
• Follow-on biologics
• followon biologics
• generic
• generic medication
• Healthcare
• healthcare reform
• hepatitis
• HIV/AIDS
• innovation
• multiple sclerosis
• rare disease